Clinical Trial Update: Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nimotuzumab with radiotherapy in high-risk head and neck squamous cell carcinoma patients not eligible for cisplatin after surgery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Eye & ENT Hospital of Fudan University | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN